Pfizer Inc. (NYSE:PFE) Shares Sold by Realta Investment Advisors

Realta Investment Advisors decreased its position in Pfizer Inc. (NYSE:PFE) by 62.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,549 shares of the biopharmaceutical company’s stock after selling 17,179 shares during the quarter. Realta Investment Advisors’ holdings in Pfizer were worth $307,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in PFE. Olistico Wealth LLC acquired a new position in Pfizer during the 2nd quarter valued at approximately $25,000. MFA Wealth Advisors LLC acquired a new position in Pfizer during the 2nd quarter valued at approximately $29,000. Quarry LP acquired a new position in Pfizer during the 2nd quarter valued at approximately $31,000. Financial Connections Group Inc. acquired a new position in Pfizer during the 2nd quarter valued at approximately $34,000. Finally, ESL Trust Services LLC acquired a new position in Pfizer during the 1st quarter valued at approximately $37,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Down 0.7 %

Shares of Pfizer stock opened at $28.09 on Friday. The stock’s fifty day moving average is $29.03 and its 200-day moving average is $28.59. The firm has a market capitalization of $159.18 billion, a PE ratio of 37.96, a price-to-earnings-growth ratio of 0.90 and a beta of 0.67. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $31.54.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. The company had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a return on equity of 16.40% and a net margin of 7.07%. Pfizer’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.17) earnings per share. Equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be issued a dividend of $0.42 per share. The ex-dividend date is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.98%. Pfizer’s dividend payout ratio is 227.03%.

Insider Activity

In other Pfizer news, Director Scott Gottlieb purchased 1,000 shares of the stock in a transaction dated Wednesday, October 30th. The shares were acquired at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the acquisition, the director now owns 10,000 shares of the company’s stock, valued at $282,400. This represents a 0.00 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.06% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts have weighed in on PFE shares. StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a research note on Wednesday, October 9th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research note on Wednesday, October 23rd. Sanford C. Bernstein initiated coverage on Pfizer in a research note on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price on the stock. UBS Group boosted their price objective on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. Finally, Barclays boosted their price objective on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Eight equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $33.58.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.